Last reviewed · How we verify
Anthrax Vaccine
The Anthrax Vaccine, developed by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), is currently marketed but lacks revenue data. A key strength is the protection it offers against anthrax, a serious infectious disease, with a key composition patent expiring in 2028. The primary risk is the potential for increased competition as the patent nears expiration.
At a glance
| Generic name | Anthrax Vaccine |
|---|---|
| Sponsor | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Natural History of Anthrax: a Study of Primary Infected, Recovered, and Exposed Individuals (SPoRE); and Evaluation of AVA-Vaccinated Recipients
- Anthrax AV7909 Boost Evaluation Study (PHASE2)
- Evaluation of Clinical Benefit and Safety Following CYFENDUS Administration for Post-Exposure Prophylaxis of Anthrax Disease.
- Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study (PHASE2)
- NasoShield Study of Safety and Immunogenicity (PHASE1)
- NasoShield in Healthy Adults to Study Safety and Immunogenicity (PHASE1)
- Ciprofloxacin BioThrax Co-Administration Study (PHASE2)
- Anthrax AV7909 Liquid vs Lyophilized (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: